Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | FABP3 | P05413 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12354198 | 1.00 | KCNQ3 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL22492062 | 1.00 | KCNQ3 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL22492058 | 1.00 | KCNQ3 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL1752024 | 0.98 | SLC6A2 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL1752183 | 0.98 | SLC6A2 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL12592461 | 0.98 | SLC6A2 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL4522521 | 0.96 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL7352068 | 0.96 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL12592455 | 0.96 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL7352063 | 0.96 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | LES LABORATOIRES SERVIER (FR) | 2022-05-17 | — | — | US | disclosed |
| CN-112368276-A | Amino-pyrimidinone derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-02-12 | — | — | CN | disclosed |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | LES LABORATOIRES SERVIER (FR) | 2020-12-31 | — | — | US | disclosed |
| EP-3717482-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Les Laboratoires Servier SAS (FR) | 2020-10-07 | — | — | EP | disclosed |
| CN-111542524-A | Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 | 法国施维雅药厂 | 2020-08-14 | — | — | CN | disclosed |
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| CN-101460461-B | Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2029541-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007113155-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC Β-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5462964-A | Administering to treat thrombosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995009858-A1 | DIPEPTIDE BORONIC ACID INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
| US-4017552-A | Bicyclo-[3'3'0]-octa-2-ene formed by isomerizing 1,5-cyclooctadiene | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4, HRH4 | KCNQ3 2115/4885KCNQ2 2516/4885SLC6A2 227/4885 |
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | USP7, PSMA7, PSMB7 | KCNQ3 4231/4885KCNQ2 3921/4885SLC6A2 4768/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | KCNQ3 3897/4885KCNQ2 4164/4885SLC6A2 2332/4885 |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | AHR, CYP8B1, ADRA2C | KCNQ3 3897/4885KCNQ2 4164/4885SLC6A2 2332/4885 |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | PSMB7, PSMA7, USP7 | KCNQ3 4378/4885KCNQ2 3943/4885SLC6A2 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.